Celldex Therapeutics (CLDX) Competitors $20.66 -0.05 (-0.24%) Closing price 04:00 PM EasternExtended Trading$20.66 0.00 (-0.02%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. IONS, ALKS, FOLD, LGND, BCRX, MNKD, DVAX, INVA, NVAX, and OPKShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals BioCryst Pharmaceuticals MannKind Dynavax Technologies Innoviva Novavax OPKO Health Celldex Therapeutics (NASDAQ:CLDX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Which has preferable valuation and earnings, CLDX or IONS? Celldex Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M195.37-$141.43M-$2.45-8.43Ionis Pharmaceuticals$705.14M7.39-$366.29M-$2.99-10.96 Do analysts rate CLDX or IONS? Celldex Therapeutics presently has a consensus target price of $55.30, suggesting a potential upside of 167.67%. Ionis Pharmaceuticals has a consensus target price of $56.67, suggesting a potential upside of 72.87%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Ionis Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Does the media refer more to CLDX or IONS? In the previous week, Ionis Pharmaceuticals had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 16 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.26 beat Ionis Pharmaceuticals' score of 1.10 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 16 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CLDX or IONS? Celldex Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Does the MarketBeat Community prefer CLDX or IONS? Ionis Pharmaceuticals received 83 more outperform votes than Celldex Therapeutics when rated by MarketBeat users. However, 75.27% of users gave Celldex Therapeutics an outperform vote while only 60.43% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes62475.27% Underperform Votes20524.73% Ionis PharmaceuticalsOutperform Votes70760.43% Underperform Votes46339.57% Do insiders and institutionals have more ownership in CLDX or IONS? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CLDX or IONS more profitable? Ionis Pharmaceuticals has a net margin of -64.25% compared to Celldex Therapeutics' net margin of -1,544.32%. Celldex Therapeutics' return on equity of -19.75% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Ionis Pharmaceuticals -64.25%-100.05%-15.70% SummaryCelldex Therapeutics beats Ionis Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37B$2.62B$5.55B$8.04BDividend YieldN/A0.75%5.09%4.22%P/E Ratio-8.047.7922.6818.83Price / Sales195.3750.78404.28106.72Price / CashN/A15.7538.1834.62Price / Book2.283.796.794.33Net Income-$141.43M-$65.73M$3.22B$247.97M7 Day Performance5.57%2.15%2.44%2.71%1 Month Performance18.87%-2.41%3.78%3.37%1 Year Performance-49.44%-11.22%17.05%5.80% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics1.9996 of 5 stars$20.66-0.2%$55.30+167.7%-47.4%$1.37B$7.02M-8.04150Upcoming EarningsPositive NewsGap UpIONSIonis Pharmaceuticals4.4017 of 5 stars$29.74+0.1%$56.72+90.7%-26.3%$4.73B$705.14M-9.78800Earnings ReportAnalyst ForecastInsider TradeNews CoveragePositive NewsALKSAlkermes4.1835 of 5 stars$27.91+0.3%$38.08+36.5%+27.4%$4.60B$1.56B12.862,280Earnings ReportAnalyst ForecastNews CoverageFOLDAmicus Therapeutics4.2683 of 5 stars$7.39+0.5%$16.75+126.7%-36.0%$2.27B$528.30M-41.06480Analyst ForecastNews CoverageLGNDLigand Pharmaceuticals4.4265 of 5 stars$108.88+0.7%$146.43+34.5%+52.8%$2.10B$167.13M43.3880Upcoming EarningsPositive NewsBCRXBioCryst Pharmaceuticals4.566 of 5 stars$8.32-0.8%$15.57+87.2%+90.6%$1.74B$450.71M-13.64530Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageMNKDMannKind3.1483 of 5 stars$4.73-0.2%$9.56+102.2%+14.1%$1.44B$285.50M67.57400Upcoming EarningsNews CoveragePositive NewsDVAXDynavax Technologies4.3134 of 5 stars$11.27+4.2%$20.50+81.9%-1.7%$1.38B$277.25M62.61350Upcoming EarningsINVAInnoviva4.2465 of 5 stars$18.38+0.8%$55.00+199.2%+22.5%$1.15B$358.71M26.64100Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6363 of 5 stars$6.70+0.4%$18.00+168.7%+37.3%$1.08B$682.16M-2.961,990Upcoming EarningsOPKOPKO Health4.4932 of 5 stars$1.41flat$2.75+95.0%+6.3%$946.89M$713.14M-7.424,200Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies Ionis Pharmaceuticals Alternatives Alkermes Alternatives Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Novavax Alternatives OPKO Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDX Stock Free CLDX Stock Alerts